一键配置港股创新药核心资产，港股通创新药ETF嘉实将于7月14日起首发

Group 1 - The core viewpoint of the articles highlights the strong performance of the Hong Kong innovative pharmaceutical sector, with the CSI Hong Kong Stock Connect Innovative Drug Index showing a 107.95% increase over the past year and a 66.23% increase year-to-date, significantly outperforming similar indices and the broader A-share and Hong Kong markets [1][2] - The innovative pharmaceutical industry in China is experiencing a turning point driven by three factors: industrial trends, performance inflection points, and policy support, indicating a new cycle of value reassessment [1][4] - The launch of the Harvest CSI Hong Kong Stock Connect Innovative Drug ETF aims to provide investors with an efficient tool to invest in leading companies in the Hong Kong innovative pharmaceutical sector [1][5] Group 2 - The CSI Hong Kong Stock Connect Innovative Drug Index includes up to 50 listed companies focused on innovative drug research and production, primarily in biopharmaceuticals and chemical pharmaceuticals, covering the entire innovative drug industry chain [2] - The top five constituent stocks of the index account for 44.09% of the total weight, while the top ten account for 68.02%, indicating a high concentration and representation of China's core innovative pharmaceutical capabilities [2][3] - The index's top ten stocks include notable companies such as Innovent Biologics, WuXi Biologics, and BeiGene, which are expected to benefit from medical consumption upgrades and policy support [3][4] Group 3 - The current investment logic for the Hong Kong innovative pharmaceutical sector is based on three advantages: high concentration of leading companies, improving industry fundamentals, and relatively low historical valuations [4] - As of July 3, the price-to-earnings ratio (TTM) of the CSI Hong Kong Stock Connect Innovative Drug Index is 34.39, which is at the 17.62% historical percentile for the past five years, indicating attractive investment value [4] - The ETF's issuance is part of a broader strategy by Harvest Fund to develop specialized ETF products in key industries, including life sciences, reflecting a commitment to passive investment strategies [5]